BioReliance has named Charles Harwood, who currently is executive chairman, to the post of interim CEO in the wake of the departure of former CEO Tim Derrington.
 
BioReliance, which Invitrogen sold in April to Avista Capital Partners for $210 million, noted that since June three senior executives have joined the company, including David Onions as CSO, David Walker as CFO, and Darryl Goss as VP of Global Process Excellence.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.

The New York Times reports that evidence linking trauma in one generation to epigenetic effects that influence subsequent generations may be overstated.

ScienceInsider reports that US National Institutes of Health researchers were told in the fall they could not obtain new human fetal tissue.

In PNAS this week: skin pigmentation evolution among KhoeSan, biomarkers for dengue virus progression, and more.